Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent

Kirihara T., Taniguchi T., Yamamura K., Iwamura R., Yoneda K., Odani-Kawabata N., Shimazaki A., Matsugi T., Shams N., Zhang J.-Z.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology

Affiliations

R & D Division, Santen Pharmaceutical Co., Ltd, Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan; R & D Division, Santen Pharmaceutical Co., Ltd, Ikoma-shi, Nara, Japan; Corporate Research & Development, Ube Industries, Ltd, Ube, Yamaguchi, Japan; R & D Division, Santen Inc, Emeryville, CA, United States

Related Publications

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

The rate of failure of trabeculectomy and tube shunt surgery in eyes with uveitic glaucoma and ocular hypertension: The purpose of this study is to look at the outcomes of trabeculectomy and tube shunt surgery in a large cohort of patients with uveitis

Groth S.L.; Newcomb C.W.; Yang W.; Payal A.; Begum H.; Khachatryan N.; Kaçmaz R.O.; Dreger K.A.; Rosenbaum J.T.; Nida Sen H.; Suhler E.B.; Thorne J.E.; Bhatt N.P.; Foster C.S.; Jabs D.A.; Levy-Clarke G.A.; Buchanich J.M.; Ying G.S.; Kempen J.H.; Gangaputra S.;

View all Glaucoma publications